Corcept Therapeutics (CORT) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Based on 4 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $165.00 from $95.00 | Jul 30, 2026 |
| Canaccord Genuity | Maintained | Buy | $161.00 from $150.00 | Jul 30, 2026 |
| Piper Sandler | Maintained | Overweight | $165.00 from $88.00 | Jul 30, 2026 |
| Canaccord Genuity | Maintained | Buy | $150.00 from $135.00 | Jul 29, 2026 |
| Wolfe Research | Downgraded | Peer Perform → Underperform | $50.00 | Jul 27, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $95.00 from $75.00 | May 28, 2026 |
| Canaccord Genuity | Maintained | Buy | $135.00 from $110.00 | May 28, 2026 |
| UBS | Upgraded | Neutral → Buy | $72.00 from $44.00 | May 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $75.00 from $60.00 | May 4, 2026 |
| Piper Sandler | Maintained | Overweight | $88.00 from $73.00 | May 1, 2026 |
| Wolfe Research | Upgraded | Underperform → Peer Perform | — | Mar 26, 2026 |
| Canaccord Genuity | Maintained | Buy | $110.00 from $100.00 | Mar 26, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $60.00 from $67.00 | Mar 25, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $60.00 from $67.00 | Feb 25, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $67.00 from $105.00 | Feb 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $105.00 from $90.00 | Jan 23, 2026 |
| Canaccord Genuity | Maintained | Buy | $100.00 from $99.00 | Jan 23, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $90.00 from $145.00 | Jan 2, 2026 |
| Canaccord Genuity | Maintained | Buy | $99.00 from $140.00 | Jan 2, 2026 |
| UBS | Initiated Coverage | Neutral | $95.00 | Dec 16, 2025 |
Frequently asked questions
What is the price target for CORT stock?
The average 12-month analyst price target for Corcept Therapeutics (CORT) is $135.25, with a high estimate of $165.00 and a low of $50.00, across 4 analysts.
Is CORT a buy, sell, or hold?
Analysts covering Corcept Therapeutics currently average a Buy rating: 5 buy, 1 hold and 1 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for CORT?
The average price target of $135.25 implies 19.32% upside from the last price of $113.35.
What is the latest analyst rating on CORT?
On Jul 30, 2026, HC Wainwright & Co. maintained Corcept Therapeutics at Buy with a price target of $165.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.